Nuo Therapeutics, Inc. (AURX) Gross margin 2015–2025
Nuo Therapeutics, Inc. (AURX) gross margin by fiscal year — reported gross profit divided by reported revenue.
66.9%FY2025 · since FY2015: 30.8% → 66.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 66.9% | -10.9 pp |
| FY2024 | 77.8% | -1.5 pp |
| FY2023 | 79.3% | -3.6 pp |
| FY2022 | 82.9% | — |
| FY2019 | 21.6% | -66.5 pp |
| FY2018 | 88.1% | +139.4 pp |
| FY2017 | -51.3% | — |
| FY2015 | 30.8% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice